Suppr超能文献

与标准血液透析和腹膜透析相比,递增血液透析治疗偶发患者的结果。

Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis.

机构信息

Division of Nephrology, Geneva University Hospitals, Geneva, Switzerland.

Division of Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.

出版信息

Nephrol Dial Transplant. 2022 Nov 23;37(12):2514-2521. doi: 10.1093/ndt/gfac205.

Abstract

BACKGROUND

Residual kidney function is considered better preserved with incremental haemodialysis (I-HD) or peritoneal dialysis (PD) as compared with conventional thrice-weekly HD (TW-HD) and is associated with improved survival. We aimed to describe outcomes of patients initiating dialysis with I-HD, TW-HD or PD.

METHODS

We conducted a retrospective analysis of a prospectively assembled cohort in a single university centre including all adults initiating dialysis from January 2013 to December 2020. Primary and secondary endpoints were overall survival and hospitalization days at 1 year, respectively.

RESULTS

We included 313 patients with 234 starting on HD (166 TW-HD and 68 I-HD) and 79 on PD. At the end of the study, 10 were still on I-HD while 45 transitioned to TW-HD after a mean duration of 9.8 ± 9.1 months. Patients who stayed on I-HD were less frequently diabetics (P = .007). Mean follow-up was 33.1 ± 30.8 months during which 124 (39.6%) patients died. Compared with patients on TW-HD, those on I-HD had improved survival (hazard ratio 0.49, 95% confidence interval 0.26-0.93, P = .029), while those on PD had similar survival. Initial kidney replacement therapy modality was not significantly associated with hospitalization days at 1 year.

CONCLUSIONS

I-HD is suitable for selected patients starting dialysis and can be maintained for a significant amount of time before transition to TW-HD, with diabetes being a risk factor. Although hospitalization days at 1 year are similar, initiation with I-HD is associated with improved survival as compared with TW-HD or PD. Results of randomized controlled trials are awaited prior to large-scale implementation of I-HD programmes.

摘要

背景

与传统每周三次血液透析(TW-HD)相比,增量血液透析(I-HD)或腹膜透析(PD)保留残余肾功能的效果更好,与生存改善相关。我们旨在描述开始接受 I-HD、TW-HD 或 PD 透析的患者的结局。

方法

我们对一个单中心前瞻性队列进行了回顾性分析,纳入了 2013 年 1 月至 2020 年 12 月期间所有开始透析的成年人。主要和次要终点分别为总生存率和 1 年时的住院天数。

结果

共纳入 313 例患者,其中 234 例开始接受 HD 治疗(166 例 TW-HD,68 例 I-HD),79 例开始接受 PD 治疗。研究结束时,10 例仍在接受 I-HD 治疗,45 例在平均 9.8±9.1 个月后转为 TW-HD。继续接受 I-HD 治疗的患者糖尿病发病率较低(P=0.007)。平均随访时间为 33.1±30.8 个月,在此期间 124 例(39.6%)患者死亡。与接受 TW-HD 治疗的患者相比,接受 I-HD 治疗的患者生存率提高(风险比 0.49,95%置信区间 0.26-0.93,P=0.029),而接受 PD 治疗的患者生存率相似。起始肾脏替代治疗方式与 1 年时的住院天数无显著相关性。

结论

I-HD 适合开始透析的部分患者,在过渡到 TW-HD 之前可以维持较长时间,糖尿病是一个危险因素。尽管 1 年时的住院天数相似,但与 TW-HD 或 PD 相比,起始接受 I-HD 治疗与生存率提高相关。在大规模实施 I-HD 项目之前,需要等待随机对照试验的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3a/9681916/d0bc6d78ad69/gfac205fig1g.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验